The Life Sciences team advised Moderna, Inc. (NASDAQ:MRNA) on its strategic partnership with the Australian Federal Government to establish a state-of-the-art, domestic mRNA vaccine manufacturing facility in Australia.
Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The company’s mRNA pipeline includes 28 vaccine candidates, including vaccines against respiratory viruses, vaccines against latent viruses, and vaccines against threats to global public health.
The facility, when constructed, is expected to provide people in Australia with access to a domestically manufactured portfolio of mRNA vaccines against respiratory viruses, including COVID-19, seasonal influenza, respiratory syncytial virus (RSV), and other potential respiratory viruses, pending licensure.
As part of the strategic partnership, Moderna expects to support Australia's mRNA research, development, and industry ecosystem, including engagement with collaborative research partnerships with Australian institutions and establishing a Regional Research Centre for respiratory medicines and tropical diseases.
Goodwin has advised Moderna since its inception over a decade ago. The Goodwin team advising the company on its strategic partnership with the Australian Government was led by Sarah Solomon and included Alexander Hernandez, Shannyn Henke, Alexandra Haas, and Xiaowei Wu.
For more details, read the press release.